Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL535279 | 0.98 | HDAC1 (0.36) | HDAC1HDAC2HDAC6HDAC3HDAC8 | |
| Hydrochloric Acid SCHEMBL949316 | 0.98 | HDAC1 (0.36) | HDAC1HDAC2HDAC6HDAC3HDAC8 | |
| SCHEMBL28580994 | 0.89 | HDAC3 (0.33) | HDAC1HDAC2HDAC6HDAC3HDAC8 | |
| SCHEMBL15653871 | 0.88 | PAOX (0.47) | HDAC1HDAC2HDAC6HDAC8CYP1A2 | |
| SCHEMBL648724 | 0.86 | CYP1A2 (0.54) | HDAC1HDAC2HDAC6HDAC3HDAC8 | |
| SCHEMBL179682 | 0.85 | CYP1A2 (0.39) | HDAC1HDAC2HDAC6HDAC3HDAC8 | |
| SCHEMBL901575 | 0.84 | CYP1A2 (0.47) | HDAC1HDAC2HDAC6HDAC3HDAC8 | |
| SCHEMBL22832200 | 0.84 | CYP1A2 (0.52) | HDAC1HDAC2HDAC6HDAC3HDAC8 | |
| Hydrochloric Acid SCHEMBL1093848 | 0.84 | CYP1A2 (0.52) | HDAC1HDAC2HDAC6HDAC3HDAC8 | |
| SCHEMBL644646 | 0.84 | TSHR (0.45) | HDAC1HDAC2HDAC6HDAC3HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1091 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109734666-B | Preparation method for synthesizing indazolinones compound by carbon dioxide promotion and photo-induction without photocatalyst | 湖南大学 | 2023-03-28 | — | — | CN | claimed |
| EP-3666767-B1 | PHTHALAZINONE DERIVATIVES, METHOD FOR THEIR PREPARATION THEREOF, PHARMACEUTICAL COMPOSITION COMPRISING THEM, AND THEIR USE | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2021-12-01 | — | — | EP | claimed |
| US-11040952-B2 | Phthalazinone compound, method for preparation thereof, pharmaceutical composition thereof, and use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2021-06-22 | — | — | US | claimed |
| CN-109134429-B | Phthalazinone compound, preparation method, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2021-06-01 | — | — | CN | claimed |
| CN-107903302-B | Preparation method of gamma-lactam bridged dipeptide compound | 韶远科技（上海)有限公司 | 2021-05-14 | — | — | CN | claimed |
| EP-3666767-A1 | PYRIDAZINONE COMPOUND, METHOD FOR PREPARATION THEREOF, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2020-06-17 | — | — | EP | claimed |
| US-20200181109-A1 | PHTHALAZINONE COMPOUND, METHOD FOR PREPARATION THEREOF, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2020-06-11 | — | — | US | claimed |
| CN-108578399-B | Application of amino acid ester compound in preparation of anti-CVB 3 virus medicine | 湖北工业大学 | 2020-01-07 | — | — | CN | claimed |
| CN-109843851-A | PH response type lipid | 夸祖鲁·纳塔尔大学 | 2019-06-04 | — | — | CN | claimed |
| CN-103865013-A | Preparation method of glucose and temperature-responsive insulin controlled release carrier | UNIV TONGJI | 2014-06-18 | — | — | CN | claimed |
| EP-1633348-A1 | 4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE - 3 - CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B sb 1 /sb RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | Elan Pharmaceuticals, Inc. (US) | 2006-03-15 | — | — | EP | claimed |
| US-20050020659-A1 | Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists | ELAN PHARMACEUTICALS, INC. | 2005-01-27 | — | — | US | claimed |
| WO-2004098589-A1 | 4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE - 3 - CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | ELAN PHARMACEUTICALS, INC. (US) | 2004-11-18 | — | — | WO | claimed |
| EP-1064253-B1 | ANTI-TUMOUR AGENTS | ASTRAZENECA AB (SE) | 2003-01-29 | — | — | EP | claimed |
| US-6346633-B1 | TERT-AMINOPHENYLESTER OF ACID | ASTRAZENECA AB (SE) | 2002-02-12 | — | — | US | claimed |
| EP-1064253-A1 | ANTI-TUMOUR AGENTS | AstraZeneca AB (SE) | 2001-01-03 | — | — | EP | claimed |
| WO-1999048857-A1 | ANTI-TUMOUR AGENTS | ASTRAZENECA AB (SE) | 1999-09-30 | — | — | WO | claimed |
| US-5908960-A | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 1999-06-01 | — | — | US | claimed |
| US-5061806-A | Phosphinic acid derivatives | MERCK & CO., INC. (US) | 1991-10-29 | — | — | US | claimed |
| US-4308168-A | ALKYLESTERS OF AMINO ACIDS, NONTOXIC | IDEMITSU KOSAN CO., LTD. (JP) | 1981-12-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200181109-A1 | PHTHALAZINONE COMPOUND, METHOD FOR PREPARATION THEREOF, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | POLRMT, POLN, HCCS | HDAC1 523/4885HDAC2 556/4885HDAC6 735/4885 |
| US-20050020659-A1 | Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists | BDKRB1, BDKRB2, BRS3 | HDAC1 2089/4885HDAC2 2249/4885HDAC6 4064/4885 |
| US-11040952-B2 | Phthalazinone compound, method for preparation thereof, pharmaceutical composition thereof, and use thereof | POLRMT, POLN, HCCS | HDAC1 523/4885HDAC2 556/4885HDAC6 735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.